

Daftar Pustaka

1. Heinrichs MT, Drusano GL, Brown DL, Maynard MS, Sy SK, Rand KH, et al. Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. *International journal of antimicrobial agents*. 2019 Mar 1;53(3):275-83
2. Gillespie SH. The role of moxifloxacin in tuberculosis therapy. *European Respiratory Review*. 2016 Mar 1;25(139):19-28.
3. World Health Organization. Baseline assessment of community based TB services in 8 WHO engage-TB priority countries. World Health Organization; 2018.
4. Kementerian Kesehatan RI. Petunjuk Teknis Pengobatan TB Resistan Obat dengan Paduan Jangka Pendek di Fasyankes TB Resistan Obat. 1–21 (2017).
5. Codecasa LR, Ferrara G, Ferrarese M, Morandi MA, Penati V, Lacchini C, et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. *Respiratory medicine*. 2006 Sep 1;100(9):1566-72
6. Liu X, Ma J, Huang L, Zhu INTENSIF, Yuan P, Wan R, et al. Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis. *Medicine*. 2017 Nov;96(44).
7. Alexandrou AJ, Duncan RS, Sullivan A, Hancox JC, Leishman DJ, Witchel HJ, et al. Mechanism of hERG K⁺ channel blockade by the fluoroquinolone antibiotic moxifloxacin. *British journal of pharmacology*. 2006 Apr 1;147(8):905-16.
8. Xu FY, Huang JH, He YC, Liang LY, Li LJ, Yang J, et al. Population pharmacokinetics of moxifloxacin and its concentration–QT interval relationship modeling in Chinese healthy volunteers. *Acta Pharmacologica Sinica*. 2017 Nov;38(11):1580.
9. Yap YG, Camm AJ. QT prolongation with quinolone antimicrobial agents. *In Quinolone Antimicrobial Agents, Third Edition 2003 Jan 1 (pp. 421-440)*. American Society of Microbiology.
10. Grosjean P, Urien S. Moxifloxacin versus placebo modeling of the QT interval. *Journal of pharmacokinetics and pharmacodynamics*. 2012 Apr 1;39(2):205-15.
11. Basingnaa A, Antwi-Baffour S, Nkansah D, Afutu E, Owusu E. Plasma Levels of Cytokines (IL-10, IFN- γ and TNF- α) in Multidrug Resistant

- Tuberculosis and Drug Responsive Tuberculosis Patients in Ghana. *Diseases*. 2019 Mar;7(1):2.
12. Fernandez-Velasco M, Ruiz-Hurtado G, Hurtado O, Moro MA, Delgado C. TNF- α downregulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation. *American Journal of Physiology-Heart and Circulatory Physiology*. 2007 Jul;293(1):H238-45.
 13. Sordillo PP, Sordillo DC, Helson L. The prolonged QT Interval: role of pro-inflammatory cytokines, reactive oxygen species and the ceramide and sphingosine-1 phosphate pathways. *in vivo*. 2015 Nov 1;29(6):619-36.
 14. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT syndrome: an emerging role for inflammation and immunity. *Frontiers in cardiovascular medicine*. 2015 May 27;2:26.
 15. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in *Mycobacterium tuberculosis*, by use of an in vitro pharmacodynamic infection model and mathematical modeling. *Journal of Infectious Diseases*. 2004 Nov 1;190(9):1642-51.
 16. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization; 2019.
 17. Kementerian Kesehatan Republik Indonesia. Panduan pelayanan tuberkulosis resistan obat untuk fasilitas pelayanan kesehatan. kementerian kesehatan Republik Indonesia; 2018
 18. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. *Therapeutic advances in drug safety*. 2012 Oct;3(5):241-53.
 19. Khan F, Ismail M, Khan Q, Ali Z. Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review. *Expert opinion on drug safety*. 2018 Oct 3;17(10):1029-39.
 20. Goldstein EJ, Owens Jr RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. *Clinical Infectious Diseases*. 2006 Dec 15;43(12):1603-11.
 21. Ambhore A, Teo SG, Omar AR, Poh KK. ECG series. Importance of QT interval in clinical practice. *Singapore medical journal*. 2014 Dec;55(12):607.

22. Camm AJ, Malik M, Yap YG. Acquired long QT syndrome. John Wiley & Sons; 2008 Apr 15.
23. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. *The Scientific World Journal*. 2012;2012.
24. Trindade MA, Cunha PA, De Araújo TA, Da Silva GM, Ferreira VS. Interaction study of moxifloxacin with Cu (II) ion using square-wave voltammetry and its application in the determination in tablets. *Eclética Química*. 2006;31(1):31-8.
25. Johannesen L, Vicente J, Mason JW, Erato C, Sanabria C, Waite-Labott K, et al. Late sodium current block for drug-induced long QT syndrome: results from a prospective clinical trial. *Clinical Pharmacology & Therapeutics*. 2016 Feb;99(2):214-23.
26. Darpo B, Garnett C, Benson CT, Keirns J, Leishman D, Malik M, et al. Cardiac Safety Research Consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward. *American heart journal*. 2014 Sep 1;168(3):262-72
27. Ponte ML, Keller GA, Girolamo GD. Mechanisms of drug induced QT interval prolongation. *Current drug safety*. 2010 Jan 1;5(1):44-53.
28. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang INTENSIF. The immunology of tuberculosis: from bench to bedside. *Respirology*. 2010 Apr;15(3):433-50.
29. Walzl G, Ronacher K, Hanekom INTENSIF, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. *Nature Reviews Immunology*. 2011 May;11(5):343.
30. Domingo-Gonzalez R, Prince O, Cooper A, Khader S. Cytokines and chemokines in Mycobacterium tuberculosis infection. *Microbiology spectrum*. 2016 Oct;4(5).
31. Parameswaran N, Patial S. Tumor necrosis factor- α signaling in macrophages. *Critical reviews in eukaryotic gene expression*. 2010;20(2):87.
32. Malagarie-Cazenave S et al. Sphingolipid signalling: molecular basis and role in TNF- α -induced cell death. *Expert reviews in molecular medicine*. 2002 Dec;4(28):1-5.

33. Dbaibo GS, Obeid LM, Hannun YA. Tumor necrosis factor-alpha (TNF-alpha) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-alpha from activation of nuclear factor-kappa B. *Journal of Biological Chemistry*. 1993 Aug 25;268(24):17762-6.
34. Andrade Júnior DR, Santos SA, Castro ID, Andrade DR. Correlation between serum tumor necrosis factor alpha levels and clinical severity of tuberculosis. *Brazilian Journal of Infectious Diseases*. 2008 Jun;12(3):226-33.
35. Cilfone NA, Perry CR, Kirschner DE, Linderman JJ. Multi-scale modeling predicts a balance of tumor necrosis factor- α and interleukin-10 controls the granuloma environment during *Mycobacterium tuberculosis* infection. *PloS one*. 2013 Jul 15;8(7):e68680.
36. Urschel K, Cicha I. TNF- α in the cardiovascular system: from physiology to therapy. *Internat J Interferon Cytokine Med Res*. 2015;7:9-25.
37. Grandy SA, Fiset C. Ventricular K⁺ currents are reduced in mice with elevated levels of serum TNF- α . *Journal of molecular and cellular cardiology*. 2009 Aug 1;47(2):238-46.
38. Pranger AD, van der Werf TS, Kosterink JG, Alffenaar JW. The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. *Drugs*. 2019 Feb 1;79(2):161-71.
39. Pranger AD et al. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. *Therapeutic drug monitoring*. 2011 Jun 1;33(3):350-4.
40. Naidoo A, Naidoo K, McIlleron INTENSIF, Essack S, Padayatchi N. A Review of Moxifloxacin for the Treatment of Drug-susceptible Tuberculosis. *The Journal of Clinical Pharmacology*. 2017 Nov;57(11):1369-86.
41. Asín-Prieto E, Rodríguez-Gascón A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. *Journal of Infection and Chemotherapy*. 2015 May 1;21(5):319-29.
42. Toutain PL, Del Castillo JR, Bousquet-Mélou A. The pharmacokinetic–pharmacodynamic approach to a rational dosage regimen for antibiotics. *Research in veterinary science*. 2002 Oct 1;73(2):105-14.
43. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. *Antimicrobial agents and Chemotherapy*. 1999 Nov 1;43(11):2793-7.

44. Boswell FJ, Andrews JM, Wise R, Dalhoff A. Bactericidal properties of moxifloxacin and post-antibiotic effect. *Journal of Antimicrobial Chemotherapy*. 1999 May 1;43(suppl_2):43-9.
45. Taubel J, Ferber G, Lorch U, Batchvarov V, Savelieva I, Camm AJ. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. *British journal of clinical pharmacology*. 2014 Jan 1;77(1):170-9.
46. Kuti JL. Optimizing antimicrobial pharmacodynamics: a guide for your stewardship program. *Revista Médica Clínica Las Condes*. 2016 Sep 1;27(5):615-24.
47. Craig WA. Does the dose matter?. *Clinical infectious diseases*. 2001 Sep 15;33(Supplement_3):S233-7.
48. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. *Antimicrobial agents and chemotherapy*. 2011 Jan 1;55(1):24-34.
49. Louie A, Duncanson B, Myrick J, Maynard M, Nole J, Brown D, et al. Activity of moxifloxacin against *Mycobacterium tuberculosis* in acid phase and nonreplicative-persister phenotype phase in a hollow-fiber infection model. *Antimicrobial agents and chemotherapy*. 2018 Dec 1;62(12):e01470-18.
50. Couderc JP et al. Improving the Detection of Subtle I Kr-Inhibition. *Drug safety*. 2008 Mar 1;31(3):249-60.
51. Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. *Journal of Antimicrobial Chemotherapy*. 2002 Apr 1;49(4):593-6.
52. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. *Clinical drug investigation*. 1999 May 1;17(5):365-87.
53. Johannesen L, Vicente J, Mason JW, Erato C, Sanabria C, Waite-Labott K, et al. Late sodium current block for drug-induced long QT syndrome: results from a prospective clinical trial. *Clinical Pharmacology & Therapeutics*. 2016 Feb;99(2):214-23.
54. Araujo FG, Slifer TL, Remington JS. Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. *Clinical microbiology and infection*. 2002 Jan 1;8(1):26-30.

55. Qiu Z, Yuan INTENSIF, Li N, Yang X, Hu X, Su F, et al. Bidirectional effects of moxifloxacin on the pro-inflammatory response in lipopolysaccharide-stimulated mouse peritoneal macrophages. *Molecular medicine reports*. 2018 Dec 1;18(6):5399-408.
56. Monastero RN, Pentyala S. Cytokines as biomarkers and their respective clinical cutoff levels. *International journal of inflammation*. 2017;2017.
57. Kemenkes RI. Keputusan Menteri Kesehatan RI Nomor: 1995/Menkes. SK/XII/2011 Tentang Standar Antropometri Penilaian Indeks Massa Tubuh (IMT) Anak. Jakarta: Kemenkes RI; 2011.
58. World Health Organization. Tuberculosis in gender. World Health Organization; 2020.
59. Nhamoyebonde S, Leslie A. Biological differences between the sexes and susceptibility to tuberculosis. *The Journal of infectious diseases*. 2014 Jul 15;209(suppl_3):S100-6.
60. Indonesia PE. pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. Pb. Perkeni. 2019.
61. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. *Clinical Infectious Diseases*. 2007 Aug 15;45(4):428-35.
62. Noubiap JJ, Nansseu JR, Nyaga UF, Nkeck JR, Endomba FT, Kaze AD, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis. *The Lancet Global Health*. 2019 Apr 1;7(4):e448-60.
63. Baumert, M., Porta, A., Vos, M.A., Malik, M., Couderc, J.P., Laguna, et al. QT interval variability in body surface ECG: measurement, physiological basis, and clinical value: position statement and consensus guidance endorsed by the European Heart Rhythm Association jointly with the ESC Working Group on Cardiac Cellular Electrophysiology. 2016. *Europace*, 18(6), pp.925-944.
64. Yang XH, Su JB, Zhang XL, Zhao LH, Xu F, Wang XQ, Cheng XB. The relationship between insulin sensitivity and heart rate-corrected QT interval in patients with type 2 diabetes. *Diabetology & metabolic syndrome*. 2017 Dec 1;9(1):69.
65. Li X, Ren H, Xu ZR, Liu YJ, Yang XP, Liu JQ. Prevalence and risk factors of prolonged QTc interval among Chinese patients with type 2 diabetes. *Experimental diabetes research*. 2012 Dec 25;2012.

66. Bonakdar HR, Aslanpour M, Moladoust H, Sadeghipour P, Mohamadi F, Rad MA, Kheirkhah J. Comparison between QT interval parameters in type 2 diabetic and nondiabetic patients with non-ST elevation myocardial infarction. *The Journal of Tehran University Heart Center*. 2014;9(4):166.
67. Fatima N, Shameem M, Khan HM. Changes in serum levels of TNF- α & IL-4 among new, under-treatment & MDR TB patients. *Microbiology Research Journal International*. 2015 Mar 16:159-66.
68. Portales-Pérez DP, Baranda L, Layseca E, Fierro NA, De la Fuente H, Rosenstein Y, González-Amaro R. Comparative and prospective study of different immune parameters in healthy subjects at risk for tuberculosis and in tuberculosis patients. *Clin. Diagn. Lab. Immunol.*. 2002 Mar 1;9(2):299-307.
69. Deveci F, Akbulut HH, Turgut T, Muz MH. Changes in serum cytokine levels in active tuberculosis with treatment. *Mediators of inflammation*. 2005;2005(5):256-62.
70. Kawaguchi H, Ina Y, Ito S, Sato S, Sugiura Y, Tomita H, et al. Serum levels of soluble tumor necrosis factor (TNF) receptors in patients with pulmonary tuberculosis. *Kekkaku (Tuberculosis)*. 1996 Mar 15;71(3):259-65.
71. Djoba Siawaya JF, Beyers N, Van Helden P, Walzl G. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. *Clinical & Experimental Immunology*. 2009 Apr;156(1):69-77.
72. Romero-Adrian TB, Leal-Montiel J, Fernández G, Valecillo A. Role of cytokines and other factors involved in the Mycobacterium tuberculosis infection. *World Journal of immunology*. 2015 Mar 27;5(1):16-50.
73. Zhou Y, Tan CY, Mo ZJ, Gao QL, He D, Li J, Huang RF, Li YB, Guo CF, Guo Q, Wang LJ. Polymorphisms in the SP110 and TNF- α gene and susceptibility to pulmonary and spinal tuberculosis among Southern Chinese population. *Disease markers*. 2017;2017.
74. Ates Ö, Musellim B, Ongen G, Topal-Sarıkaya A. Interleukin-10 and tumor necrosis factor- α gene polymorphisms in tuberculosis. *Journal of clinical immunology*. 2008 May 1;28(3):232-6.
75. Ukibe NR, Ukibe SN, Onwubuya EI, Onyenekwe CC, Monago IN, Emelumadu OF, et al. Possible impact of variations in some Cytokine levels during menstrual cycle in women of reproductive age infected with Pulmonary Tuberculosis at Nnewi, Nigeria'. *Clinical Investigation*. 2018;8(2):63-73.

76. Bini EI, Espinosa DM, Castillo BM, Payán JB, Colucci D, Cruz AF, Zatarain ZL, Alfonseca E, Pardo MR, Bottasso O, Pando RH. The influence of sex steroid hormones in the immunopathology of experimental pulmonary tuberculosis. *PloS one*. 2014;9(4).
77. Mesquita ED, Gil-Santana L, Ramalho D, Tonomura E, Silva EC, Oliveira MM, Andrade BB, Kritski A, Rede-TB Study Group. Associations between systemic inflammation, mycobacterial loads in sputum and radiological improvement after treatment initiation in pulmonary TB patients from Brazil: a prospective cohort study. *BMC infectious diseases*. 2016 Dec 1;16(1):368.
78. Eum SY, Lee YJ, Min JH, Kwak HK, Hong MS, Kong JH, Hwang SH, Park SK, LeBlanc JJ, Via LE, Barry III CE. Association of antigen-stimulated release of tumor necrosis factor-alpha in whole blood with response to chemotherapy in patients with pulmonary multidrug-resistant tuberculosis. *Respiration*. 2010;80(4):275-84.
79. Borst SE. The role of TNF- α in insulin resistance. *Endocrine*. 2004 Mar 1;23(2-3):177-82.
80. Gwozdziwiczová S, Lichnovská R, Yahia RB, Chlup R, Hřebíček J. TNF-alpha in the development of insulin resistance and other disorders in metabolic syndrome. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2005 Jul 1;149(1):109-17.
81. Vink AS, Neumann B, Lieve KV, Sinner MF, Hofman N, El Kadi S, Schoenmaker MH, Slaghekke HM, de Jong JS, Clur SA, Blom NA. Determination and interpretation of the QT interval: Comprehensive analysis of a large cohort of long QT syndrome patients and controls. *Circulation*. 2018 Nov 20;138(21):2345-58.
82. Baumert, M., Porta, A., Vos, M.A., Malik, M., Couderc, J.P., Laguna, P., et al. QT interval variability in body surface ECG: measurement, physiological basis, and clinical value: position statement and consensus guidance endorsed by the European Heart Rhythm Association jointly with the ESC Working Group on Cardiac Cellular Electrophysiology. 2016. *Europace*, 18(6), pp.925-944.